#24: H/X @ ASCO 2012

On June 1, 2012, Healthios/SJA (Chicago-based investment bank) sponsored an industry Partnering Forum, H/X @ ASCO 2012. 51 "Strategic" large pharma/biotech and emerging growth companies attended the Forum participating in over 180 meetings. Scientific platforms/biologic pathways profiled by leading emerging growth biotechnology companies included: CSCs, CSF-1R, EGFR, ErbB3, HGF/SF, LSD1, P53, Raf, RNAi, Syk, TGFβ, Tie-2, VEGFR, WT1.

Participating "Strategic" Large Pharma/Biotech

Abbott Laboratories, Amgen, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Celgene, EMD Serono, Forest Laboratories, GlaxoSmithKline, Ipsen, MedImmune, Merck, Millennium Pharma, Novartis, Pfizer, Pierre Fabry, Roche, Sanofi, Sunovion and Teva Pharmaceuticals.

Participating Emerging Growth Biotechnology Companies

Ambit Biosciences, Ambrx, Acceleron Pharma, Ambit Bioscience, Array BioPharma, AVEO, BetaCat Pharmaceuticals, BIND Biosciences, Cerulean Pharma, Cleave Biosciences, Cylene Pharma, Dicerna Pharmaceuticals, Eleison Pharmaceuticals, Eleven Biotherapeutics, Fate Therapeutics, Formula Pharmaceuticals, Halozyme, Immunocellular Therapeutics, IRX Therapeutics, KaloBios Pharmaceuticals, ParinGenix, Pathwork Diagnostics, Portola Pharmaceuticals, Proacta Therapeutics, Salarius Pharmaceuticals, Theracrine, Tragara Pharmaceuticals, and Verastem.
Back to Blog